You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on EGFR biomarkers.
The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
The company is evaluating the HER3-directed antibody-drug conjugate in previously treated patients with EGFR-mutated non-small cell lung cancer.
News items for the week of Jan. 25, 2021.
The firm will submit to regulators data from a Phase I/II trial, in which 28 percent of patients previously on platinum chemo responded to the drug.
Although the pandemic may have been at the forefront of readers' minds, they remained interested in the latest advances and controversies in precision oncology.
The company submitted data on amivantamab as a treatment for metastatic non-small cell lung cancer patients with EGFR exon 20 insertion mutations.
Zai Lab will pay Cullinan $20 million upfront to license the drug in Greater China and could pay up to $211 million in future milestones and royalties.
The agency made its decision based on data showing adjuvant Tagrisso decreased the risk of cancer recurrence or death by 80 percent compared to placebo.
The study is evaluating the drug in previously treated NSCLC patients with alterations in EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET.
Janssen's biologics license application for amivantamab is the first regulatory submission for a drug to target lung cancer patients with EGFR exon 20 mutations.